Lyell Immunopharma, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for LYEL, updated each market day.
LYEL AI Sentiment
AI predicts Lyell Immunopharma, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Sector
Exchange
Market Cap
$556,382,101
Cap Tier
Employees
161
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
June 17, 2021
Website
LYEL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
LYEL Volatility
Lyell Immunopharma, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
